In treatment experienced HCQ/SSZ/LEF with mod-high disease activity RA, what is the recommended switch?

In treatment experienced HCQ/SSZ/LEF with mod-high disease activity RA, what is the recommended switch?

• A. Add a bDMARDs
• B. Switch to MTX
• C. Switch to MTX and LEF
• D. Switch to HCQ/SSZ/LEF

Answer: (B)

Starting methotrexate is the best next move because it serves as the foundational DMARD backbone for rheumatoid arthritis. Methotrexate has the strongest, most consistent evidence for reducing disease activity and slowing joint damage, and it pairs well with other agents if more control is needed. In this scenario, the patient is already on hydroxychloroquine, sulfasalazine, and leflunomide but has not used methotrexate. Introducing methotrexate provides a proven, effective core therapy before escalations such as adding biologics or JAK inhibitors. If disease activity remains high after starting methotrexate, further escalation can be considered. The other options either repeat a regimen that’s already being used, or propose adding or switching to therapies that aren’t the first step when MTX-naive in this context.

Starting methotrexate is the best next move because it serves as the foundational DMARD backbone for rheumatoid arthritis. Methotrexate has the strongest, most consistent evidence for reducing disease activity and slowing joint damage, and it pairs well with other agents if more control is needed. In this scenario, the patient is already on hydroxychloroquine, sulfasalazine, and leflunomide but has not used methotrexate. Introducing methotrexate provides a proven, effective core therapy before escalations such as adding biologics or JAK inhibitors. If disease activity remains high after starting methotrexate, further escalation can be considered. The other options either repeat a regimen that’s already being used, or propose adding or switching to therapies that aren’t the first step when MTX-naive in this context.